Third-line chemotherapy for resistant Hodgkin's disease with lomustine, etoposide, and methotrexate
- Author
- TSENG, A. JR1 ; JACOBS, C; COLEMAN, C. N; HORNING, S. J; LEWIS, B. J; ROSENBERG, S. A
[1] Univ. California San Francisco medical cent., cancer res. inst., San Francisco CA 94143, United States - Source
Cancer treatment reports. 1987, Vol 71, Num 5, pp 475-478 ; ref : 28 ref
- CODEN
- CTRRDO
- ISSN
- 0361-5960
- Scientific domain
- Medical oncology; Pharmacology drugs
- Publisher
- National Institute of Health, Silver Spring, MD
/
US Department of Health, Education and Welfare, Silver Spring, MD
- Publication country
- United States
- Document type
- Article
- Language
- English
- Keyword (fr)
- Anticancéreux Antimétabolite Homme Hémopathie maligne Lomustine Lymphogranulomatose maligne Méthotrexate Nitrosourées Polychimiothérapie Voie orale Étoposide
- Keyword (en)
- Antineoplastic agent Antimetabolic Human Malignant hemopathy Hodgkin disease Nitrosoureas Polychemotherapy Oral administration
- Keyword (es)
- Anticanceroso Antimetabolito Hombre Hemopatia maligna Linfogranulomatosis maligna Nitrosoureas Poliquimioterapia Via oral
- Classification
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B02 Pharmacology. Drug treatments / 002B02R Antineoplastic agents / 002B02R02 Chemotherapy
- Discipline
- Pharmacological treatments
- Origin
- Inist-CNRS
- Database
- PASCAL
- INIST identifier
- 8295516
Sauf mention contraire ci-dessus, le contenu de cette notice bibliographique peut être utilisé dans le cadre d’une licence CC BY 4.0 Inist-CNRS / Unless otherwise stated above, the content of this bibliographic record may be used under a CC BY 4.0 licence by Inist-CNRS / A menos que se haya señalado antes, el contenido de este registro bibliográfico puede ser utilizado al amparo de una licencia CC BY 4.0 Inist-CNRS
Install on your browser
"O:13:\"PanistOpenUrl\":36:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000idc\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:0:\"\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:99:\"Third-line chemotherapy for resistant Hodgkin's disease with lomustine, etoposide, and methotrexate\";s:9:\"\u0000*\u0000jtitle\";s:24:\"Cancer treatment reports\";s:9:\"\u0000*\u0000stitle\";s:17:\"Cancer treat. rep\";s:7:\"\u0000*\u0000date\";s:4:\"1987\";s:9:\"\u0000*\u0000volume\";s:2:\"71\";s:8:\"\u0000*\u0000issue\";s:1:\"5\";s:8:\"\u0000*\u0000spage\";s:3:\"475\";s:8:\"\u0000*\u0000epage\";s:3:\"478\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0361-5960\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:5:\"TSENG\";s:10:\"\u0000*\u0000aufirst\";s:5:\"A. JR\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:5:{i:0;s:9:\"JACOBS, C\";i:1;s:13:\"COLEMAN, C. N\";i:2;s:13:\"HORNING, S. J\";i:3;s:11:\"LEWIS, B. J\";i:4;s:15:\"ROSENBERG, S. A\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"CTRRDO\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:99:\"Third-line chemotherapy for resistant Hodgkin's disease with lomustine, etoposide, and methotrexate\";s:8:\"\u0000*\u0000place\";s:17:\"Silver Spring, MD\";s:6:\"\u0000*\u0000pub\";s:28:\"National Institute of Health\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:0:\"\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Panist access
"O:12:\"IstexOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:0:\"\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:99:\"Third-line chemotherapy for resistant Hodgkin's disease with lomustine, etoposide, and methotrexate\";s:9:\"\u0000*\u0000jtitle\";s:24:\"Cancer treatment reports\";s:9:\"\u0000*\u0000stitle\";s:17:\"Cancer treat. rep\";s:7:\"\u0000*\u0000date\";s:4:\"1987\";s:9:\"\u0000*\u0000volume\";s:2:\"71\";s:8:\"\u0000*\u0000issue\";s:1:\"5\";s:8:\"\u0000*\u0000spage\";s:3:\"475\";s:8:\"\u0000*\u0000epage\";s:3:\"478\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0361-5960\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:5:\"TSENG\";s:10:\"\u0000*\u0000aufirst\";s:5:\"A. JR\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:5:{i:0;s:9:\"JACOBS, C\";i:1;s:13:\"COLEMAN, C. N\";i:2;s:13:\"HORNING, S. J\";i:3;s:11:\"LEWIS, B. J\";i:4;s:15:\"ROSENBERG, S. A\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"CTRRDO\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:99:\"Third-line chemotherapy for resistant Hodgkin's disease with lomustine, etoposide, and methotrexate\";s:8:\"\u0000*\u0000place\";s:17:\"Silver Spring, MD\";s:6:\"\u0000*\u0000pub\";s:28:\"National Institute of Health\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:0:\"\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Istex access
"O:16:\"EuropePMCOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:0:\"\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:99:\"Third-line chemotherapy for resistant Hodgkin's disease with lomustine, etoposide, and methotrexate\";s:9:\"\u0000*\u0000jtitle\";s:24:\"Cancer treatment reports\";s:9:\"\u0000*\u0000stitle\";s:17:\"Cancer treat. rep\";s:7:\"\u0000*\u0000date\";s:4:\"1987\";s:9:\"\u0000*\u0000volume\";s:2:\"71\";s:8:\"\u0000*\u0000issue\";s:1:\"5\";s:8:\"\u0000*\u0000spage\";s:3:\"475\";s:8:\"\u0000*\u0000epage\";s:3:\"478\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0361-5960\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:5:\"TSENG\";s:10:\"\u0000*\u0000aufirst\";s:5:\"A. JR\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:5:{i:0;s:9:\"JACOBS, C\";i:1;s:13:\"COLEMAN, C. N\";i:2;s:13:\"HORNING, S. J\";i:3;s:11:\"LEWIS, B. J\";i:4;s:15:\"ROSENBERG, S. A\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"CTRRDO\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:99:\"Third-line chemotherapy for resistant Hodgkin's disease with lomustine, etoposide, and methotrexate\";s:8:\"\u0000*\u0000place\";s:17:\"Silver Spring, MD\";s:6:\"\u0000*\u0000pub\";s:28:\"National Institute of Health\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:0:\"\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Europe PubMed Central access
"O:11:\"BaseOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:0:\"\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:99:\"Third-line chemotherapy for resistant Hodgkin's disease with lomustine, etoposide, and methotrexate\";s:9:\"\u0000*\u0000jtitle\";s:24:\"Cancer treatment reports\";s:9:\"\u0000*\u0000stitle\";s:17:\"Cancer treat. rep\";s:7:\"\u0000*\u0000date\";s:4:\"1987\";s:9:\"\u0000*\u0000volume\";s:2:\"71\";s:8:\"\u0000*\u0000issue\";s:1:\"5\";s:8:\"\u0000*\u0000spage\";s:3:\"475\";s:8:\"\u0000*\u0000epage\";s:3:\"478\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0361-5960\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:5:\"TSENG\";s:10:\"\u0000*\u0000aufirst\";s:5:\"A. JR\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:5:{i:0;s:9:\"JACOBS, C\";i:1;s:13:\"COLEMAN, C. N\";i:2;s:13:\"HORNING, S. J\";i:3;s:11:\"LEWIS, B. J\";i:4;s:15:\"ROSENBERG, S. A\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"CTRRDO\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:99:\"Third-line chemotherapy for resistant Hodgkin's disease with lomustine, etoposide, and methotrexate\";s:8:\"\u0000*\u0000place\";s:17:\"Silver Spring, MD\";s:6:\"\u0000*\u0000pub\";s:28:\"National Institute of Health\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:0:\"\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Base Search access
"O:12:\"ArXivOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:0:\"\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:99:\"Third-line chemotherapy for resistant Hodgkin's disease with lomustine, etoposide, and methotrexate\";s:9:\"\u0000*\u0000jtitle\";s:24:\"Cancer treatment reports\";s:9:\"\u0000*\u0000stitle\";s:17:\"Cancer treat. rep\";s:7:\"\u0000*\u0000date\";s:4:\"1987\";s:9:\"\u0000*\u0000volume\";s:2:\"71\";s:8:\"\u0000*\u0000issue\";s:1:\"5\";s:8:\"\u0000*\u0000spage\";s:3:\"475\";s:8:\"\u0000*\u0000epage\";s:3:\"478\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0361-5960\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:5:\"TSENG\";s:10:\"\u0000*\u0000aufirst\";s:5:\"A. JR\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:5:{i:0;s:9:\"JACOBS, C\";i:1;s:13:\"COLEMAN, C. N\";i:2;s:13:\"HORNING, S. J\";i:3;s:11:\"LEWIS, B. J\";i:4;s:15:\"ROSENBERG, S. A\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"CTRRDO\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:99:\"Third-line chemotherapy for resistant Hodgkin's disease with lomustine, etoposide, and methotrexate\";s:8:\"\u0000*\u0000place\";s:17:\"Silver Spring, MD\";s:6:\"\u0000*\u0000pub\";s:28:\"National Institute of Health\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:0:\"\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
arXiv access
